Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1772740 | 0.98 | BACE1 (0.56) | BACE1CYP1A2CYP2D6DRD2KDM4E | |
| SCHEMBL7411503 | 0.82 | BACE1 (0.51) | BACE1CYP1A2CYP2D6DRD2KDM4E | |
| SCHEMBL7418163 | 0.77 | BACE1 (0.46) | BACE1CYP1A2CYP2D6DRD2KDM4E | |
| SCHEMBL12844946 | 0.76 | DRD2 (0.47) | BACE1DRD2NPY5RTRPA1LMNA | |
| SCHEMBL8470 | 0.76 | DRD2 (0.47) | BACE1DRD2MAPTNPY5RTRPA1 | |
| SCHEMBL20829220 | 0.76 | DRD2 (0.47) | BACE1DRD2NPY5RTRPA1LMNA | |
| SCHEMBL12778506 | 0.76 | DRD2 (0.47) | BACE1DRD2NPY5RTRPA1LMNA | |
| SCHEMBL85731 | 0.76 | DRD2 (0.47) | BACE1DRD2KDM4EMAPTRECQL | |
| SCHEMBL5577003 | 0.76 | NPY5R (0.40) | BACE1CYP1A2CYP2D6DRD2KDM4E | |
| SCHEMBL20708485 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420807-B2 | Process for the preparation of quetiapine | FERMION OY (FI) | 2013-04-16 | — | — | US | claimed |
| EP-2245021-B1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2012-09-12 | — | — | EP | claimed |
| US-20110112290-A1 | PROCESS FOR THE PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2011-05-12 | — | — | US | claimed |
| EP-2245021-A1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE | Fermion Oy (FI) | 2010-11-03 | — | — | EP | claimed |
| WO-2009095529-A1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2009-08-06 | — | — | WO | claimed |
| US-9650341-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-05-16 | — | — | US | disclosed |
| CN-103304515-A | Method for preparing 11-amino dibenzo [b, f] [1,4] thiazepine | UNIV EAST CHINA NORMAL | 2013-09-18 | — | — | CN | disclosed |
| US-8420807-B2 | Process for the preparation of quetiapine | FERMION OY (FI) | 2013-04-16 | — | — | US | disclosed |
| US-8420807-B2 | Process for the preparation of quetiapine | FERMION OY (FI) | 2013-04-16 | — | — | US | disclosed |
| US-8420807-B2 | Process for the preparation of quetiapine | FERMION OY (FI) | 2013-04-16 | — | — | US | disclosed |
| US-8420807-B2 | Process for the preparation of quetiapine | FERMION OY (FI) | 2013-04-16 | — | — | US | disclosed |
| EP-2245021-B1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2012-09-12 | — | — | EP | disclosed |
| US-20090082334-A1 | DEUTERIUM-ENRICHED QUETIAPINE | PROTIA, LLC (US) | 2009-03-26 | — | — | US | disclosed |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS ) (FR) | 2007-02-08 | — | — | US | disclosed |
| WO-2007004234-A1 | A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE | USV LIMITED (IN) | 2007-01-11 | — | — | WO | disclosed |
| EP-1551992-B1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NAT RECH SCIENT (FR) | 2006-12-27 | — | — | EP | disclosed |
| US-20060172337-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-08-03 | — | — | US | disclosed |
| WO-2005028457-A1 | PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005028457-A1 | PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005028457-A1 | PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112290-A1 | PROCESS FOR THE PREPARATION OF QUETIAPINE | CYP3A5, QDPR, HTR5A | BACE1 330/4885CYP1A2 34/4885CYP2D6 8/4885 |
| US-20070031821-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | ATXN2L, ATXN10, CLN6 | BACE1 2428/4885CYP1A2 4312/4885CYP2D6 1782/4885 |
| US-20090082334-A1 | DEUTERIUM-ENRICHED QUETIAPINE | SLC6A3, SLC6A4, SLC6A2 | BACE1 643/4885CYP1A2 877/4885CYP2D6 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.